186 related articles for article (PubMed ID: 36977915)
41. Pan-cancer analyses of clinical prognosis, immune infiltration, and immunotherapy efficacy for TRPV family using multi-omics data.
Shen C; Fu C; Suo Y; Li K; Zhang Z; Yang S; Zhang Y; Lin Y; Li Z; Wu Z; Huang S; Chen H; Fan Z; Hu H
Heliyon; 2023 Jun; 9(6):e16897. PubMed ID: 37346342
[TBL] [Abstract][Full Text] [Related]
42. Diagnostic and therapeutic values of PMEPA1 and its correlation with tumor immunity in pan-cancer.
Wang B; Zhong JL; Li HZ; Wu B; Sun DF; Jiang N; Shang J; Chen YF; Xu XH; Lu HD
Life Sci; 2021 Jul; 277():119452. PubMed ID: 33831430
[TBL] [Abstract][Full Text] [Related]
43. Immune infiltration is associated with pan-cancer prognostic biomarker RING finger protein 187.
Fan XT; Gao BF; Wang XF; Zhou K; Zhao Y; Yuan J
J Mol Recognit; 2024 Mar; 37(2):e3071. PubMed ID: 38167828
[TBL] [Abstract][Full Text] [Related]
44. ARPC2: A Pan-Cancer Prognostic and Immunological Biomarker That Promotes Hepatocellular Carcinoma Cell Proliferation and Invasion.
Huang S; Dong C; Li D; Xu Y; Wu J
Front Cell Dev Biol; 2022; 10():896080. PubMed ID: 35733852
[No Abstract] [Full Text] [Related]
45. TMEM158 promotes pancreatic cancer aggressiveness by activation of TGFβ1 and PI3K/AKT signaling pathway.
Fu Y; Yao N; Ding D; Zhang X; Liu H; Ma L; Shi W; Zhu C; Tang L
J Cell Physiol; 2020 Mar; 235(3):2761-2775. PubMed ID: 31531884
[TBL] [Abstract][Full Text] [Related]
46. The value of
Feng Y; Wang Y; Guo K; Feng J; Shao C; Pan M; Ding P; Liu H; Duan H; Lu D; Wang Z; Zhang Y; Zhang Y; Han J; Li X; Yan X
Ann Transl Med; 2022 Apr; 10(8):466. PubMed ID: 35571400
[TBL] [Abstract][Full Text] [Related]
47. Comprehensive pan-cancer analysis reveals the prognostic value and immunological role of SPIB.
Ding M; Li Q; Tan X; Zhang L; Tan J; Zheng L
Aging (Albany NY); 2022 Aug; 14(15):6338-6357. PubMed ID: 35969172
[TBL] [Abstract][Full Text] [Related]
48. Pan-Cancer Integrated Analysis Identification of SASH3, a Potential Biomarker That Inhibits Lung Adenocarcinoma Progression.
Chen X; Yuan Y; Ren W; Zhou F; Huang X; Pu J; Niu X; Jiang X
Front Oncol; 2022; 12():927988. PubMed ID: 35756681
[TBL] [Abstract][Full Text] [Related]
49. Prognostic value and immunological role of PDCD1 gene in pan-cancer.
Miao Y; Wang J; Li Q; Quan W; Wang Y; Li C; Wu J; Mi D
Int Immunopharmacol; 2020 Dec; 89(Pt B):107080. PubMed ID: 33069926
[TBL] [Abstract][Full Text] [Related]
50. A Pan-Cancer Analysis Reveals the Prognostic and Immunotherapeutic Value of Stanniocalcin-2 (STC2).
Jiang ZH; Shen X; Wei Y; Chen Y; Chai H; Xia L; Leng W
Front Genet; 2022; 13():927046. PubMed ID: 35937984
[No Abstract] [Full Text] [Related]
51. RelB is a potential molecular biomarker for immunotherapy in human pan-cancer.
Wu J; Yu X; Zhu H; Chen P; Liu T; Yin R; Qiang Y; Xu L
Front Mol Biosci; 2023; 10():1178446. PubMed ID: 37388242
[No Abstract] [Full Text] [Related]
52. Biological and immunological significance of DLL3 expression in different tumor tissues: a pan-cancer analysis.
Zhang Y; Shang L; Han J; Shen X; Liu H; Yang J; Shi H
Aging (Albany NY); 2023 Apr; 15(9):3427-3441. PubMed ID: 37179118
[TBL] [Abstract][Full Text] [Related]
53. XRCC1: a potential prognostic and immunological biomarker in LGG based on systematic pan-cancer analysis.
Wang G; Li Y; Pan R; Yin X; Jia C; She Y; Huang L; Yang G; Chi H; Tian G
Aging (Albany NY); 2024 Jan; 16(1):872-910. PubMed ID: 38217545
[TBL] [Abstract][Full Text] [Related]
54. Ferroptosis-related gene HIC1 in the prediction of the prognosis and immunotherapeutic efficacy with immunological activity.
Wu Y; Lin Z; Tang X; Tong Z; Ji Y; Xu Y; Zhou Z; Yang J; Li Z; Liu T
Front Immunol; 2023; 14():1182030. PubMed ID: 37388742
[TBL] [Abstract][Full Text] [Related]
55. RFC2: a prognosis biomarker correlated with the immune signature in diffuse lower-grade gliomas.
Zhao X; Wang Y; Li J; Qu F; Fu X; Liu S; Wang X; Xie Y; Zhang X
Sci Rep; 2022 Feb; 12(1):3122. PubMed ID: 35210438
[TBL] [Abstract][Full Text] [Related]
56. Zic Family Member 2 (ZIC2): a Potential Diagnostic and Prognostic Biomarker for Pan-Cancer.
Lv Z; Qi L; Hu X; Mo M; Jiang H; Fan B; Li Y
Front Mol Biosci; 2021; 8():631067. PubMed ID: 33665207
[No Abstract] [Full Text] [Related]
57. Pan-Cancer Analysis Based on
Zhang Y; Wang S; Han S; Feng Y
Front Oncol; 2022; 12():844794. PubMed ID: 35359375
[TBL] [Abstract][Full Text] [Related]
58. The prognostic value and immunological role of CD44 in pan-cancer study.
Chen S; Zhang S; Chen S; Ma F
Sci Rep; 2023 Apr; 13(1):7011. PubMed ID: 37117249
[TBL] [Abstract][Full Text] [Related]
59. Prognostic and Immunological Significance of CXCR2 in Ovarian Cancer: A Promising Target for Survival Outcome and Immunotherapeutic Response Assessment.
Ji H; Ren M; Liu T; Sun Y
Dis Markers; 2021; 2021():5350232. PubMed ID: 34840630
[TBL] [Abstract][Full Text] [Related]
60. Pan-cancer analysis of the prognostic and immunological role of BRCA1-associated protein 1 gene (BAP1): Friend or foe?
Wang T; Zhu T; Zhang Y; Bai J; Xue Y; Xu G; Lu L; Peng Q
Gene; 2022 Oct; 840():146765. PubMed ID: 35905855
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]